Pituitary responsiveness to GH‐releasing hormone, GH‐releasing peptide‐2 and thyrotrophin‐releasing hormone in critical illness

OBJECTIVE Protein hypercatabolism and preservation of fat depots are hallmarks of critical illness, which is associated with blunted pulsatile GH secretion and low circulating IGF‐I, TSH, T4 and T3. Repetitive TRH administration is known to reactivate the pituitary‐thyroid axis and to evoke paradoxical GH release in critical illness. We further explored the hypothalamic‐pituitary function in critical illness by examining the effects of GH‐releasing hormone (GHRH) and/or GH‐releasing peptide‐2 (GHRP‐2) and TRH administration.

[1]  C. Scanes,et al.  Neuroendocrine-Immune Interactions , 1994, Journal of Neuroimmunology.

[2]  F. Casanueva,et al.  Absence of growth hormone (GH) secretion after the administration of either GH-releasing hormone (GHRH), GH-releasing peptide (GHRP-6), or GHRH plus GHRP-6 in children with neonatal pituitary stalk transection. , 1995, The Journal of clinical endocrinology and metabolism.

[3]  C. Bowers,et al.  GH responses to intravenous bolus infusions of GH releasing hormone and GH releasing peptide 2 separately and in combination in adult volunteers , 1995, Clinical endocrinology.

[4]  M. Jeevanandam,et al.  Plasma levels of insulin-like growth factor binding protein-3 in acute trauma patients. , 1995, Metabolism: clinical and experimental.

[5]  B. Imbimbo,et al.  Comparison of the effects of growth hormone-releasing hormone and hexarelin, a novel growth hormone-releasing peptide-6 analog, on growth hormone secretion in humans with or without glucocorticoid excess. , 1995, The Journal of endocrinology.

[6]  J. Kinney.  Metabolic responses of the critically ill patient. , 1995, Critical care clinics.

[7]  M. Elia.  Changing concepts of nutrient requirements in disease: implications for artificial nutritional support , 1995, The Lancet.

[8]  J. Nauta,et al.  Effects of human growth hormone in critically ill nonseptic patients: results from a prospective, randomized, placebo-controlled trial. , 1995, Critical care medicine.

[9]  M. Korbonits,et al.  Growth hormone-releasing peptide and its analogues Novel stimuli to growth hormone release , 1995, Trends in Endocrinology & Metabolism.

[10]  D. Carta,et al.  The growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, in short normal and obese children and in hypopituitary subjects. , 1995, The Journal of clinical endocrinology and metabolism.

[11]  B A Mizock,et al.  Alterations in carbohydrate metabolism during stress: a review of the literature. , 1995, The American journal of medicine.

[12]  V. Lenaerts,et al.  Metabolic modulation of the growth hormone-releasing activity of hexarelin in man. , 1995, Metabolism: clinical and experimental.

[13]  F. Zegher,et al.  Dopamine and the sick euthyroid syndrome in critical illness , 1994, Clinical endocrinology.

[14]  F. Zegher,et al.  Luteinizing hormone secretion and hypoandrogenaemia in critically ill men: effect of dopamine , 1994, Clinical endocrinology.

[15]  M. Kawamata,et al.  Suppression of the thyrotropin response to thyrotropin‐releasing hormone and its association with severity of critical illness , 1994, Critical care medicine.

[16]  G. Van den Berghe,et al.  Growth hormone secretion in critical illness: effect of dopamine. , 1994, The Journal of clinical endocrinology and metabolism.

[17]  P. Hindmarsh,et al.  Low-dose growth hormone-releasing hormone tests: a dose-response study. , 1994, European Journal of Endocrinology.

[18]  G. Verleden,et al.  Growth hormone as a rescue treatment after heart-lung or double-lung transplantation , 1994 .

[19]  K. Meert,et al.  Alterations in immune function following head injury in children. , 1995, Critical care medicine.

[20]  D. Wilmore,et al.  Metabolic Support of the Critically Ill Patient , 1993, Update in Intensive Care and Emergency Medicine.

[21]  E. Krenning,et al.  The sick euthyroid syndrome: changes in thyroid hormone serum parameters and hormone metabolism , 1993, Clinical endocrinology.

[22]  M. Kaplan,et al.  Reduced tissue thyroid hormone levels in fatal illness. , 1993, Metabolism: clinical and experimental.

[23]  A. Ho,et al.  Mechanisms of action of a second generation growth hormone-releasing peptide (Ala-His-D-beta Nal-Ala-Trp-D-Phe-Lys-NH2) in rat anterior pituitary cells. , 1993, Endocrinology.

[24]  R. Baxter,et al.  Enhancement of the anabolic effects of growth hormone and insulin-like growth factor I by use of both agents simultaneously. , 1993, The Journal of clinical investigation.

[25]  F. Casanueva,et al.  Effect of growth hormone (GH)-releasing hormone (GHRH), atropine, pyridostigmine, or hypoglycemia on GHRP-6-induced GH secretion in man. , 1993, The Journal of clinical endocrinology and metabolism.

[26]  G. Reisz,et al.  Effects of dopamine on T‐lymphocyte proliferative responses and serum prolactin concentrations in critically ill patients , 1992, Critical care medicine.

[27]  C. E. Lyons,et al.  Pituitary adenylate cyclase activating polypeptide, growth hormone (GH)-releasing peptide and GH-releasing hormone stimulate GH release through distinct pituitary receptors. , 1992, Endocrinology.

[28]  J. Holly,et al.  Levels of GH binding activity, IGFBP‐1, insulin, blood glucose and cortisol in intensive care patients , 1991, Clinical endocrinology.

[29]  F. Roelfsema,et al.  The interaction of GHRH with TRH in acromegaly: a controlled study. , 1991, Acta endocrinologica.

[30]  D. Wilmore.  Catabolic illness. Strategies for enhancing recovery. , 1991, The New England journal of medicine.

[31]  J. Miell,et al.  Critically ill patients have high basal growth hormone levels with attenuated oscillatory activity associated with low levels of insulin–like growth factor‐I , 1991, Clinical endocrinology.

[32]  T. Badger,et al.  On the actions of the growth hormone-releasing hexapeptide, GHRP. , 1991, Endocrinology.

[33]  L. Broemeling,et al.  Effects of recombinant human growth hormone on donor-site healing in severely burned children. , 1990, Annals of surgery.

[34]  E. van Cauter,et al.  Physiological role of somatostatin on growth hormone regulation in humans. , 1990, Metabolism: clinical and experimental.

[35]  M. Thorner,et al.  Growth hormone (GH)-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormone. , 1990, The Journal of clinical endocrinology and metabolism.

[36]  C. Marchesi,et al.  Growth hormone responses to growth hormone-releasing hormone, clonidine and insulin-induced hypoglycemia in normal weight bulimic women. , 1990, Neuropsychobiology.

[37]  D. McRitchie,et al.  Impaired antibody production in blunt trauma. Possible role for T cell dysfunction. , 1990, Archives of surgery.

[38]  M. Thorner,et al.  Intracellular calcium concentration and growth hormone secretion in individual somatotropes: effects of growth hormone-releasing factor and somatostatin. , 1988, Endocrinology.

[39]  W. Vale,et al.  Growth hormone and prolactin responses to bolus and sustained infusions of GRH-1-40-OH in man , 1987, Journal of endocrinological investigation.

[40]  A. Beddoe,et al.  Aggressive nutritional support does not prevent protein loss despite fat gain in septic intensive care patients. , 1987, The Journal of trauma.

[41]  R. Cohen,et al.  Pituitary stimulation by combined administration of four hypothalamic releasing hormones in normal men and patients. , 1986, The Journal of clinical endocrinology and metabolism.

[42]  A. Grossman,et al.  THE INTERACTION OF GROWTH HORMONE RELEASING HORMONE WITH OTHER HYPOTHALAMIC HORMONES ON THE RELEASE OF ANTERIOR PITUITARY HORMONES , 1986, Clinical endocrinology.

[43]  D. Coy,et al.  Growth hormone responses to growth hormone-releasing hormine (1–29)-NH2 and a D-Ala2 analog in normal men , 1985, Peptides.

[44]  E. Levy,et al.  Changes in mitogen responsiveness lymphocyte subsets after traumatic injury: relation to development of sepsis. , 1984, Clinical immunology and immunopathology.

[45]  F. Momany,et al.  Conformational energy studies and in vitro and in vivo activity data on growth hormone-releasing peptides. , 1984, Endocrinology.

[46]  F. Momany,et al.  On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. , 1984, Endocrinology.

[47]  P. Dannies.  The Anterior Pituitary Gland , 1984, The Yale Journal of Biology and Medicine.

[48]  R. Evans,et al.  Transcriptional regulation of growth hormone gene expression by growth hormone-releasing factor , 1983, Nature.

[49]  W. Waldhäusl,et al.  Impaired secretion of TSH in critically ill patients with 'low T4-syndrome'. , 1982, Acta endocrinologica.

[50]  K. Burman,et al.  Alterations in thyroid function in patients with systemic illness: the "euthyroid sick syndrome". , 1982, Endocrine reviews.

[51]  R L Hintz,et al.  Somatomedin-C mediates growth hormone negative feedback by effects on both the hypothalamus and the pituitary. , 1981, Science.

[52]  H. Krüskemper,et al.  Secondary hypothyroidism in severe non thyroidal illness? , 1981, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[53]  J. Meakins,et al.  Delayed Hypersensitivity: Indicator of Acquired Failure of Host Defenses in Sepsis and Trauma , 1977, Annals of surgery.

[54]  R. Sawhney,et al.  Serum levels of thyrotropin, thyroid hormones and their response to thyrotropin releasing hormone in infective febrile illnesses. , 1977, The Journal of clinical endocrinology and metabolism.

[55]  P. D. de Moor,et al.  Heterogeneity of human growth hormone in serum. , 1974, Annales d'endocrinologie.

[56]  P. Snyder,et al.  Response to thyrotropin releasing hormone (TRH) in normal man. , 1972, The Journal of clinical endocrinology and metabolism.